Takayasu Kurata

Summary

Affiliation: Kinki University
Country: Japan

Publications

  1. doi Efficacy and safety of denosumab for the treatment of bone metastases in patients with advanced cancer
    Takayasu Kurata
    Department of Medical Oncology, Kinki University School of Medicine, Osaka Sayama, Osaka, Japan
    Jpn J Clin Oncol 42:663-9. 2012
  2. doi A phase I/II study of carboplatin plus gemcitabine for elderly patients with advanced non-small cell lung cancer: West Japan Thoracic Oncology Group Trial (WJTOG) 2905
    Takayasu Kurata
    Department of Medical Oncology, Kinki University School of Medicine, 377 2 Ohno Higashi, Osaka Sayama, Osaka 589 8511, Japan
    Lung Cancer 77:110-5. 2012
  3. doi A phase I study of gemcitabine plus irinotecan for advanced NSCLC: Japan Clinical Oncology Group Trial (JCOG9904)
    Takayasu Kurata
    Department of Medical Oncology, Kinki University School of Medicine, Osaka Sayama, Osaka 589 8511, Japan
    Jpn J Clin Oncol 40:992-4. 2010
  4. doi A phase I study of topotecan plus carboplatin for relapsed SCLC: WJTOG trial
    Takayasu Kurata
    Department of Medical Oncology, Kinki University, School of Medicine, Osaka Sayama, Osaka, Japan
    J Thorac Oncol 4:644-8. 2009
  5. doi Phase III trial comparing oral S-1 plus carboplatin with paclitaxel plus carboplatin in chemotherapy-naïve patients with advanced non-small-cell lung cancer: results of a west Japan oncology group study
    Isamu Okamoto
    Kinki University Faculty of Medicine, Osaka City General Hospital, 377 2 Ohno Higashi, Osaka Sayama, Osaka 589 8511, Japan
    J Clin Oncol 28:5240-6. 2010
  6. ncbi A phase I study of irinotecan in combination with amrubicin for advanced lung cancer patients
    Hiroyasu Kaneda
    Department of Medical Oncology, Kinki University School of Medicine, Osaka 589 8511, Japan
    Anticancer Res 26:2479-85. 2006
  7. ncbi Phase I study of combination therapy with S-1 and weekly docetaxel for advanced gastric cancer
    Tomohiro Ozaki
    Department of Medical Oncology, Kinki University School of Medicine, Nara Hospital, Otoda, Ikoma, Nara, Japan
    Anticancer Res 27:2657-65. 2007
  8. doi Phase I dose-escalation and pharmacokinetic trial of lapatinib (GW572016), a selective oral dual inhibitor of ErbB-1 and -2 tyrosine kinases, in Japanese patients with solid tumors
    Kazuhiko Nakagawa
    Kinki University School of Medicine, 377 2 Ohnohigashi, Osakasayama, Osaka 589 0014, Japan
    Jpn J Clin Oncol 39:116-23. 2009
  9. doi A phase I study of S-1 with concurrent radiotherapy in elderly patients with locally advanced non-small cell lung cancer
    Yoshikazu Hasegawa
    Department of Medical Oncology, Kishiwada City Hospital, Osaka, Japan
    Invest New Drugs 31:599-604. 2013
  10. doi Response rate is associated with prolonged survival in patients with advanced non-small cell lung cancer treated with gefitinib or erlotinib
    Kazuyuki Tsujino
    Department of Respiratory Medicine, Allergy and Rheumatic Diseases, Osaka University Graduate School of Medicine, Osaka, Japan
    J Thorac Oncol 4:994-1001. 2009

Collaborators

Detail Information

Publications24

  1. doi Efficacy and safety of denosumab for the treatment of bone metastases in patients with advanced cancer
    Takayasu Kurata
    Department of Medical Oncology, Kinki University School of Medicine, Osaka Sayama, Osaka, Japan
    Jpn J Clin Oncol 42:663-9. 2012
    ..In this article, the efficacy and safety of denosumab for the treatment of bone metastases in patients with various advanced cancers are discussed...
  2. doi A phase I/II study of carboplatin plus gemcitabine for elderly patients with advanced non-small cell lung cancer: West Japan Thoracic Oncology Group Trial (WJTOG) 2905
    Takayasu Kurata
    Department of Medical Oncology, Kinki University School of Medicine, 377 2 Ohno Higashi, Osaka Sayama, Osaka 589 8511, Japan
    Lung Cancer 77:110-5. 2012
    ..However, it is unclear whether elderly patients with a good performance status can tolerate platinum-doublet chemotherapy like younger patients...
  3. doi A phase I study of gemcitabine plus irinotecan for advanced NSCLC: Japan Clinical Oncology Group Trial (JCOG9904)
    Takayasu Kurata
    Department of Medical Oncology, Kinki University School of Medicine, Osaka Sayama, Osaka 589 8511, Japan
    Jpn J Clin Oncol 40:992-4. 2010
    ..We could not determine the recommended dose of this combination because of intolerable toxicities and no efficacy. Therefore, it is difficult to forward this combination chemotherapy toward further studies...
  4. doi A phase I study of topotecan plus carboplatin for relapsed SCLC: WJTOG trial
    Takayasu Kurata
    Department of Medical Oncology, Kinki University, School of Medicine, Osaka Sayama, Osaka, Japan
    J Thorac Oncol 4:644-8. 2009
    ..A phase I study on relapsed small cell lung cancer (SCLC) was conducted to establish the toxicity and maximum tolerated dose of carboplatin with topotecan, and to observe the antitumor activity...
  5. doi Phase III trial comparing oral S-1 plus carboplatin with paclitaxel plus carboplatin in chemotherapy-naïve patients with advanced non-small-cell lung cancer: results of a west Japan oncology group study
    Isamu Okamoto
    Kinki University Faculty of Medicine, Osaka City General Hospital, 377 2 Ohno Higashi, Osaka Sayama, Osaka 589 8511, Japan
    J Clin Oncol 28:5240-6. 2010
    ....
  6. ncbi A phase I study of irinotecan in combination with amrubicin for advanced lung cancer patients
    Hiroyasu Kaneda
    Department of Medical Oncology, Kinki University School of Medicine, Osaka 589 8511, Japan
    Anticancer Res 26:2479-85. 2006
    ....
  7. ncbi Phase I study of combination therapy with S-1 and weekly docetaxel for advanced gastric cancer
    Tomohiro Ozaki
    Department of Medical Oncology, Kinki University School of Medicine, Nara Hospital, Otoda, Ikoma, Nara, Japan
    Anticancer Res 27:2657-65. 2007
    ..The primary objective of this study was to determine the maximum tolerated dose (MTD), the toxicity profile and the recommended dose (RD) for phase II of a combination of S-1 and weekly administration of docetaxel...
  8. doi Phase I dose-escalation and pharmacokinetic trial of lapatinib (GW572016), a selective oral dual inhibitor of ErbB-1 and -2 tyrosine kinases, in Japanese patients with solid tumors
    Kazuhiko Nakagawa
    Kinki University School of Medicine, 377 2 Ohnohigashi, Osakasayama, Osaka 589 0014, Japan
    Jpn J Clin Oncol 39:116-23. 2009
    ....
  9. doi A phase I study of S-1 with concurrent radiotherapy in elderly patients with locally advanced non-small cell lung cancer
    Yoshikazu Hasegawa
    Department of Medical Oncology, Kishiwada City Hospital, Osaka, Japan
    Invest New Drugs 31:599-604. 2013
    ....
  10. doi Response rate is associated with prolonged survival in patients with advanced non-small cell lung cancer treated with gefitinib or erlotinib
    Kazuyuki Tsujino
    Department of Respiratory Medicine, Allergy and Rheumatic Diseases, Osaka University Graduate School of Medicine, Osaka, Japan
    J Thorac Oncol 4:994-1001. 2009
    ..However, a relationship between clinical response and survival benefit has not been well studied in the patients treated with molecular targeted agents...
  11. doi Human papilloma virus in non-small cell lung cancer in never smokers: a systematic review of the literature
    Yoshikazu Hasegawa
    Department of Medical Oncology, Izumi Municipal Hospital, Osaka, Japan Electronic address
    Lung Cancer 83:8-13. 2014
    ..There were different patterns of HPV prevalence between Asian and European countries in the never smokers as well as in ever smokers. ..
  12. doi Switching addictions between HER2 and FGFR2 in HER2-positive breast tumor cells: FGFR2 as a potential target for salvage after lapatinib failure
    Koichi Azuma
    Department of Medical Oncology, Kinki University Faculty of Medicine, 377 2 Ohnohigashi, Osakasayama, Osaka 589 8511, Japan
    Biochem Biophys Res Commun 407:219-24. 2011
    ....
  13. ncbi Skeletal metastases in non-small cell lung cancer: a retrospective study
    Asuka Tsuya
    Department of Medical Oncology, Kinki University School of Medicine, 377 2 Ohno Higashi, Osaka Sayama City, Osaka 589 8511, Japan
    Lung Cancer 57:229-32. 2007
    ..Therefore, we planned a retrospective study to investigate the clinical impact of SREs, and to compare differences in the therapeutic outcome between patients with and without skeletal metastases or SRE...
  14. ncbi Amrubicin for non-small-cell lung cancer and small-cell lung cancer
    Takayasu Kurata
    Department of Medical Oncology, Kinki University School of Medicine, 377 2 Ohno Higashi, Osaka Sayama, Osaka 589 8511, Japan
    Invest New Drugs 25:499-504. 2007
    ..6 and 10.3 months, and 1-year survival rate was 46 and 40%, respectively. These results are promising for the treatment of both NSCLC and SCLC. Further clinical trials will clarify the status of amrubicin in the treatment of lung cancer...
  15. ncbi Amrubicin for the treatment of advanced lung cancer
    Takayasu Kurata
    Osaka Medical College, Division of Cancer Chemotherapy Center, Takatsuki, Osaka, Japan
    Expert Opin Drug Metab Toxicol 5:171-80. 2009
    ..The preclinical, pharmacology and clinical data of amrubicin for the treatment of advanced lung cancer are reviewed...
  16. ncbi Phase I study of TZT-1027, a novel synthetic dolastatin 10 derivative and inhibitor of tubulin polymerization, which was administered to patients with advanced solid tumors on days 1 and 8 in 3-week courses
    Kenji Tamura
    Department of Medical Oncology, Kinki University School of Medicine, Osaka, Japan
    Cancer Chemother Pharmacol 60:285-93. 2007
    ....
  17. doi First report of the safety, tolerability, and pharmacokinetics of the Src kinase inhibitor saracatinib (AZD0530) in Japanese patients with advanced solid tumours
    Yasuhito Fujisaka
    Osaka Medical College, Osaka, Japan
    Invest New Drugs 31:108-14. 2013
    ..Saracatinib (AZD0530) is a selective, oral Src inhibitor that has demonstrated antitumour activity in preclinical studies...
  18. doi Phase I trial of OTS11101, an anti-angiogenic vaccine targeting vascular endothelial growth factor receptor 1 in solid tumor
    Hidetoshi Hayashi
    Department of Medical Oncology, Kinki University Faculty of Medicine, Osaka Sayama, Osaka, Japan
    Cancer Sci 104:98-104. 2013
    ..In conclusion, OTS11101 was well tolerated in patients up to 3.0 mg once weekly and our biomarker analysis suggested that this anti-angiogenesis vaccine is biologically active...
  19. ncbi [Evidence-based practice guideline for unresectable advanced lung cancer in 2003]
    Masahiro Fukuoka
    Department of Medical Oncology, Kinki University School of Medicine
    Nihon Geka Gakkai Zasshi 105:412-6. 2004
    ..Recent randomized controlled trial demonstrated that irinotecan and cisplatin is superior to etoposide and cisplatin, a standard treatment of extensive-disease SCLC. This practice guideline should be updated periodically...
  20. ncbi Pemetrexed-induced edema of the eyelid
    Takayasu Kurata
    Department of Medical Oncology, Kinki University School of Medicine, 377 2 Ohno Higashi Osaka Sayama, Osaka 589 8511, Japan
    Lung Cancer 54:241-2. 2006
    ..We experienced a patient who developed the valuable edema of the eyelid. We believe that medical oncologists should be aware of this rare adverse event, although the mechanism responsible for it is not yet known...
  21. ncbi Retrospective analysis of the predictive factors associated with the response and survival benefit of gefitinib in patients with advanced non-small-cell lung cancer
    Hiroyasu Kaneda
    Department of Medical Oncology, Kinki University School of Medicine, 377 2 Ohno Higashi, Osaka Sayama, Osaka 589 8511, Japan
    Lung Cancer 46:247-54. 2004
    ..We have retrospectively reviewed data of all patients who received a single regimen of gefitinib in our institution from August 1998 until July 2003...
  22. ncbi Small interfering RNA targeting survivin sensitizes lung cancer cell with mutant p53 to adriamycin
    Kimio Yonesaka
    Department of Medical Oncology, Kinki University School of Medicine, Osaka Sayama, Osaka, Japan
    Int J Cancer 118:812-20. 2006
    ..siRNA targeting of survivin could be potentially useful for increasing sensitivity to anticancer drugs, especially in drug-resistant cells with mutated p53...
  23. ncbi Is the importance of achieving stable disease different between epidermal growth factor receptor tyrosine kinase inhibitors and cytotoxic agents in the second-line setting for advanced non-small cell lung cancer?
    Takayasu Kurata
    Department of Medical Oncology, Kinki University School of Medicine, Osaka, Japan
    J Thorac Oncol 1:684-91. 2006
    ....
  24. pmc Gemcitabine: efficacy in the treatment of advanced stage nonsquamous non-small cell lung cancer
    Hidetoshi Hayashi
    Department of Medical Oncology, Kinki University School of Medicine, Osaka Sayama, Japan
    Clin Med Insights Oncol 5:177-84. 2011
    ..This is a review of the past trials and reviews of first-line treatment for advanced NSCLC, focusing on efficacy and safety of treatment with gemcitabine according to histological subtype...